Israel Launches Groundbreaking Clinical Trial Using Ecstasy to Treat PTSD
Translated & summarized from Channel 13 by baba
Israel has launched its first clinical trial using MDMA (ecstasy) to treat PTSD patients under medical supervision. Professor Eitan Friedman stated the treatment is safe and effective, based on prior U.S. studies. The trial aims to provide new solutions for trauma survivors, with Friedman noting the widespread impact of trauma across the Israeli population.
The story in 5 lines · by baba
- Israel's first clinical trial will use MDMA to treat PTSD patients in a supervised medical setting.
- Professor Eitan Friedman confirmed the treatment is safe and effective under medical supervision.
- The trial builds on previous research conducted in the United States.
- The study aims to offer innovative solutions for trauma survivors.
- Professor Friedman noted that trauma affects the entire nation, not just soldiers.
Israel has initiated a pioneering clinical trial, the first of its kind in the country, to treat individuals suffering from Post-Traumatic Stress Disorder (PTSD) using MDMA, commonly known as ecstasy. The research, conducted within a supervised medical setting, aims to offer innovative solutions for trauma survivors, drawing upon findings from previous studies conducted in the United States.
Professor Eitan Friedman, Director of the Genetic Institute for Early Detection at Assuta, detailed the study in an interview, emphasizing that it is a controlled clinical trial overseen by the Ministry of Health. He stated that the treatment has been proven safe when administered under medical supervision and has demonstrated effectiveness in reducing the clinical rates of PTSD.
Friedman also highlighted the national imperative to prevent and identify trauma victims, reflecting on the broad societal impact of trauma in Israel. He noted that the issue extends beyond soldiers, suggesting that the entire nation is currently experiencing a form of collective trauma.
